Intratumoral Microbiota Impacts the First-Line Treatment Efficacy and Survival in Non-Small Cell Lung Cancer Patients Free of Lung Infection

Overview

Journal J Healthc Eng

Specialty Biomedical Engineering

Date 2022 Feb 18

PMID 35178229

Authors

Miao Zhang

Yan Zhang

Yi Sun

Shaochun Wang

Huan Liang

Yaguang Han

Affiliations

Soon will be listed here.

Abstract

Background: It has been known that there are microecology disorders during lung cancer development. Theoretically, intratumoral microbiota (ITM) can impact the lung cancer (LC) survival and treatment efficacy. This study conducted a follow-up investigation of non-small cell lung cancer (NSCLC) patients without lung infection to prove whether ITM indeed impacts the first-line treatment efficacy and survival.

Methods: We enrolled all patients diagnosed with NSCLC in our department from 2017 to 2019, whose tumor samples were available (through surgery or biopsy) and sent for pathogen-targeted sequencing. All patients received the first-line treatment according to the individual situation. In the short term, the efficacy of the first-line treatment was recorded. During the follow-up, the survival status, progress events, and overall survival (OS) period were recorded if a patient was contacted.

Results: Firstly, 53 patients were included, and our following analysis focused on the stage III and stage IV cases with ADC, SCC, or ASC tumors (47 cases). Several bacteria are associated with the LC status and progression, including N stages, metastasis sites, epidermal growth factor receptor (EGFR) mutation, first-line outcome, and later survival. The risk bacteria include , , , and ; and the protective (against LC development and progression) ones include and . In the logistic regression, the two-year survival can be predicted using the results of four bacteria (, , , and ), with an accuracy rate of 90.7%.

Conclusion: ITM have links to malignancy, EGFR mutation, first-line outcome, and survival of NSCLC. Our results implied the potential anti-NSCLC activity of antibiotics when used reasonably. It is still necessary to deepen the understanding of the characteristics of ITM and its interactions with NSCLC tumors and the immune cells, which is significant in individualized approaches to the LC treatment.

Citing Articles

Progress in the Study of Intratumoral Microorganisms in Hepatocellular Carcinoma.

Song Y, Tian S, Li Z, Miao J, Wu M, Xu T J Hepatocell Carcinoma. 2025; 12():59-76.

PMID: 39845367 PMC: 11752873. DOI: 10.2147/JHC.S496964.

Synergistic Potential of Antibiotics with Cancer Treatments.

Nardo G, Pantziarka P, Conti M Cancers (Basel). 2025; 17(1.

PMID: 39796688 PMC: 11718857. DOI: 10.3390/cancers17010059.

The intra-tumoral microbiome as a potential biomarker of response to external beam radiation therapy in cervical cancer.

Dou Z, Ai C, Zhang J, Li K, Jiang M, Wu X J Transl Med. 2024; 22(1):972.

PMID: 39468630 PMC: 11514760. DOI: 10.1186/s12967-024-05774-8.

Global research trends on the associations between the microbiota and lung cancer: a visualization bibliometric analysis (2008-2023).

Zhao M, Tian J, Hou W, Yin L, Li W Front Microbiol. 2024; 15:1416385.

PMID: 39282557 PMC: 11392740. DOI: 10.3389/fmicb.2024.1416385.

Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review.

Guardamagna M, Meyer M, Berciano-Guerrero M, Mesas-Ruiz A, Cobo-Dols M, Perez-Ruiz E Transl Lung Cancer Res. 2024; 13(8):2050-2066.

PMID: 39263011 PMC: 11384476. DOI: 10.21037/tlcr-24-216.

References

Belluomini L, Caldart A, Avancini A, Dodi A, Trestini I, Kadrija D . Infections and Immunotherapy in Lung Cancer: A Bad Relationship?. Int J Mol Sci. 2020; 22(1). PMC: 7793072. DOI: 10.3390/ijms22010042. View

Keren N, Konikoff F, Paitan Y, Gabay G, Reshef L, Naftali T . Interactions between the intestinal microbiota and bile acids in gallstones patients. Environ Microbiol Rep. 2015; 7(6):874-80. DOI: 10.1111/1758-2229.12319. View

Jiang L, Ren H, Zhou H, Zhao S, Hou B, Yan J . Simultaneous Detection of 13 Key Bacterial Respiratory Pathogens by Combination of Multiplex PCR and Capillary Electrophoresis. Biomed Environ Sci. 2017; 30(8):549-561. DOI: 10.3967/bes2017.074. View

Wei M, Shi S, Liang C, Meng Q, Hua J, Zhang Y . The microbiota and microbiome in pancreatic cancer: more influential than expected. Mol Cancer. 2019; 18(1):97. PMC: 6526613. DOI: 10.1186/s12943-019-1008-0. View

Hosgood 3rd H, Sapkota A, Rothman N, Rohan T, Hu W, Xu J . The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. Environ Mol Mutagen. 2014; 55(8):643-51. PMC: 4217127. DOI: 10.1002/em.21878. View

Rajagopala S, Vashee S, Oldfield L, Suzuki Y, Venter J, Telenti A . The Human Microbiome and Cancer. Cancer Prev Res (Phila). 2017; 10(4):226-234. DOI: 10.1158/1940-6207.CAPR-16-0249. View

Chang Y, Hsu M, Tu S, Yen J, Lee Y, Fang H . Metatranscriptomic Analysis of Human Lung Metagenomes from Patients with Lung Cancer. Genes (Basel). 2021; 12(9). PMC: 8466605. DOI: 10.3390/genes12091458. View

Llagostera E, Soto-Cerrato V, Montaner B, Perez-Tomas R . Prodigiosin induces apoptosis by acting on mitochondria in human lung cancer cells. Ann N Y Acad Sci. 2004; 1010:178-81. DOI: 10.1196/annals.1299.030. View

Halley A, Leonetti A, Gregori A, Tiseo M, Deng D, Giovannetti E . The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer. Anticancer Res. 2020; 40(9):4807-4818. DOI: 10.21873/anticanres.14484. View

10.

Ran Z, Liu J, Wang F, Xin C, Shen X, Zeng S . [Analysis of Pulmonary Microbial Diversity in Patients with Advanced Lung Cancer Based on High-throughput Sequencing Technology]. Zhongguo Fei Ai Za Zhi. 2020; 23(12):1031-1038. PMC: 7786226. DOI: 10.3779/j.issn.1009-3419.2020.103.16. View

11.

Vande Voorde J, Balzarini J, Liekens S . Mycoplasmas and cancer: focus on nucleoside metabolism. EXCLI J. 2015; 13:300-22. PMC: 4464442. View

12.

Xia Q, Chen G, Ren Y, Zheng T, Shen C, Li M . Investigating efficacy of "microbiota modulation of the gut-lung Axis" combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial. BMC Cancer. 2021; 21(1):721. PMC: 8220724. DOI: 10.1186/s12885-021-08448-6. View

13.

Liu G, Gu A, E M . [Mechanism and Research Progress of Microbiome in the Development of Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2020; 23(11):948-953. PMC: 7679216. DOI: 10.3779/j.issn.1009-3419.2020.101.38. View

14.

Garcia-Castillo V, Sanhueza E, McNerney E, Onate S, Garcia A . Microbiota dysbiosis: a new piece in the understanding of the carcinogenesis puzzle. J Med Microbiol. 2016; 65(12):1347-1362. DOI: 10.1099/jmm.0.000371. View

15.

Huang D, Su X, Yuan M, Zhang S, He J, Deng Q . The characterization of lung microbiome in lung cancer patients with different clinicopathology. Am J Cancer Res. 2019; 9(9):2047-2063. PMC: 6780665. View

16.

Ternak G, Berenyi K, Sumegi A, Szenczi A, Fodor B, Nemeth B . Antibiotic Consumption Patterns in European Countries May Be Associated with the Incidence of Major Carcinomas. Antibiotics (Basel). 2020; 9(10). PMC: 7601152. DOI: 10.3390/antibiotics9100643. View

17.

Sethi V, Kurtom S, Tarique M, Lavania S, Malchiodi Z, Hellmund L . Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response. Gastroenterology. 2018; 155(1):33-37.e6. PMC: 6035070. DOI: 10.1053/j.gastro.2018.04.001. View

18.

Kosikowska U, Biernasiuk A, Rybojad P, Los R, Malm A . Haemophilus parainfluenzae as a marker of the upper respiratory tract microbiota changes under the influence of preoperative prophylaxis with or without postoperative treatment in patients with lung cancer. BMC Microbiol. 2016; 16:62. PMC: 4823876. DOI: 10.1186/s12866-016-0679-6. View

19.

Hamada K, Yoshimura K, Hirasawa Y, Hosonuma M, Murayama M, Narikawa Y . Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy. Anticancer Res. 2021; 41(10):4985-4993. DOI: 10.21873/anticanres.15312. View

20.

Greathouse K, White J, Vargas A, Bliskovsky V, Beck J, von Muhlinen N . Interaction between the microbiome and TP53 in human lung cancer. Genome Biol. 2018; 19(1):123. PMC: 6109311. DOI: 10.1186/s13059-018-1501-6. View